A phaseIIIrandomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia – theTEAM‐ET2·0 trial-Reference-Cited by-同舟云学术

A phaseIIIrandomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia – theTEAM‐ET2·0 trial

Published:2019-03-28 Issue:4 Volume:185 Page:691-700
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Gisslinger Heinz¹,Buxhofer‐Ausch Veronika²,Hodisch Juri³,Radinoff Atanas⁴,Karyagina Elena⁵,Kyrcz‐Krzemień Slawomira⁶,Abdulkadyrov Kudrat⁷,Gerbutavicius Rolandas⁸,Melikyan Anait⁹,Burgstaller Sonja¹⁰,Hus Marek¹¹,Kłoczko Janusz¹²,Yablokova Vera¹³,Tzvetkov Nikolay¹⁴,Całbecka Malgorzata¹⁵,Shneyder Tatyana¹⁶,Warzocha Krzysztof¹⁷,Jurgutis Mindaugas¹⁸,Kaplanov Kamil¹⁹,Jilma Bernd²⁰^ORCID,Schoergenhofer Christian²⁰^ORCID,Klade Christoph³

Affiliation:

1. Department of Haematology and Blood Coagulation Medical University of Vienna Vienna Austria

2. Department of Internal Medicine Krankenhaus der Elisabethinen Linz Linz Austria

3. AOP Orphan Pharmaceuticals AG Vienna Austria

4. Clinic of Oncology and Haematology Tokuda Hospital Sofia Sofia Bulgaria

5. City Hospital 15 St. Petersburg Russian Federation

6. Samodzielny Publiczny Szpital Kliniczny im Andrzeja Mielęckiego Śląskiego Uniwersytetu Medycznego w Katowicach Katowice Poland

7. Russian Scientific‐Research Institute for Haematology and Transfusiology St. Petersburg Russian Federation

8. LSMU Hospital Kauno Clinics Haematology Clinic Kaunas Lithuania

9. Haemotology Research Centre Moscow Russian Federation

10. Abteilung für Innere Medizin IV Klinikum Wels‐Grieskirchen Wels Austria

11. Klinika Hematoonkologii i Transplantacji Szpiku Lublin Poland

12. Klinika Hematologii z Pododziałem Chorób Naczyń Uniwersytecki Szpital Kliniczny w Białymstoku Białystok Poland

13. Yaroslavl Regional Clinical Hospital Yaroslavl Russian Federation

14. MHAT Dr. Georgi Stranski Clinic of Haematology Pleven Bulgaria

15. Oddział Hematologii Specjalistyczny Szpital Miejski im. M. Kopernika w Toruniu Torun Poland

16. Leningrad Regional Clinical Hospital St. Petersburg Russian Federation

17. Instytut Hematologii i Transfuzjologii Warsaw Poland

18. Klaipeda Seamen's Hospital Klaipeda Lithuania

19. Volgograd Regional Clinical Oncology Dispensary Volgograd Russian Federation

20. Department of Clinical Pharmacology Medical University of Vienna Vienna Austria

Funder

AOP Orphan Pharmaceuticals

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.15824

Reference34 articles.

1. Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers;Abe Andes W.;Thrombosis and Haemostasis,1984

2. The gene expression signature of anagrelide provides an insight into its mechanism of action and uncovers new regulators of megakaryopoiesis

3. How to manage thrombosis in myeloproliferative neoplasms

4. Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

5. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A multicenter, open-label study for efficacy and safety evaluation of anagrelide in patients with treatment-naïve, high-risk essential thrombocythemia as a primary treatment;Frontiers in Oncology;2022-11-23

2. Current Concepts of Pathogenesis and Treatment of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms;Hämostaseologie;2021-06

3. Current management strategies for polycythemia vera and essential thrombocythemia;Blood Reviews;2020-07

4. Emerging drugs for essential thrombocythemia;Expert Opinion on Emerging Drugs;2019-04-03